Seagen Inc. (SGEN)

212.55 -3.61 (-1.67%) At close: 04:00PM EDT

Seagen Inc.

21823 30th Drive SE
Bothell, WA 98021
United States
425 527 4000
https://www.seagen.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3,256

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David R. Epstein B.Sc., M.B.A.	CEO & Director	1.39M	N/A	1962
Mr. Todd E. Simpson	Chief Financial Officer	1.26M	N/A	1961
Dr. Vaughn B. Himes Ph.D.	Chief Technical Officer	1.08M	3.16M	1961
Ms. Jean I. Liu J.D., M.S.	Chief Legal Officer & Corp. Sec.	1.23M	1.27M	1968
Mr. Charles R. Romp	Exec. VP of Commercial U.S.	1.08M	N/A	1968
Dr. Roger D. Dansey M.D.	Chief Medical Officer and Pres of R&D	2.48M	6.2M	1956
Mr. William Compton	Sr. VP of Global Information Technology & CIO	N/A	N/A	N/A
Mr. David Caouette	VP of Corp. Communications	N/A	N/A	N/A
Mr. Matt Skelton	VP of Marketing	N/A	N/A	N/A
Ms. Peggy M. Pinkston	Chief HR Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Corporate governance

Seagen Inc.’s ISS governance QualityScore as of 1 September 2023 is 7. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.